EKF: Stable H1 2026 results with improved margins and strong outlook for H2 and FY 2026

Revenue and gross margin remained stable in H1 2026, with Life Sciences driving growth and Point-of-Care set for recovery in H2. Adjusted EBITDA rose 2.4%, and the company remains confident in meeting FY 2026 guidance, supported by a strong order book and ongoing strategic investments.Original docu…